Estrogen alternati tr - Softcover

Steven R. Goldstein, M.D., is a professor at the New York University School of Medicine, and director of the Gynecological Ultrasound Department at NYU Medical Center. He is the author of two textbooks and numerous research articles. He lives in New York City.

This book will be sought out by women wishing to know more about Evista, Eli Lilly's trade name for raloxifene, which received FDA approval in January 1998 for the prevention of osteoporosis. Goldstein, a member of the advisory board for the team that developed raloxifene, and Ashner, a journalist and therapist, provide help in assessing the benefits and side effects of this new therapy, which benefits bones and lipid profile while significantly reducing the risk of breast cancer linked to traditional hormone replacement therapy (HRT). The authors emphasize that raloxifene and other SERMs (estrogen substitutes) are approved for use by postmenopausal women. HRT remains the treatment of choice for hot flashes and other symptoms experienced during menopause; postmenopausal women can benefit from raloxifene, which acts like estrogen in the bones and cardiovascular tissues but not in the reproductive system. For those who choose not to take estrogens during menopause, the authors offer suggestions for coping with symptoms. Recommended.?Jodith Janes, Cleveland Clinic Foundation
Copyright 1998 Reed Business Information, Inc.